Drug Trial Radar · NCT07208058
A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Nov 21, 2025
Primary completion
Dec 20, 2026
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- TJ Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study designed to evaluate the efficacy, safety, immunogenicity, PK, and PD characteristics of Plonmarlimab in patients with relapsed/refractory rheumatic and immunologic disease-associated MAS, and to explore biomarkers related to the efficacy of Plonmarlimab.
Conditions
- Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis
Interventions
PlonmarlimabDrug
Subjects will receive Plonmarlimab 10 mg/kg by intravenous injection once weekly from Week 1 to Week 3, and Plonmarlimab 6 mg/kg by intravenous injection once weekly from Week 4 to Week 8 (10 mg/kg QW×3 + 6 mg/kg QW×5).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate (ORR)Time frame: at the end of Week 8
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
The Second Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China · Recruiting
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
Henan Children's Hospital Zhengzhou Children's Hospital
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China · Withdrawn
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China · Withdrawn
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.